Ursodeoxycholic acid therapy in cystic fibrosis liver disease - A retrospective long-term follow-up case-control study

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 3, 2012, Pages 266-273

  Kappler, M ^a   Espach, C ^a   Schweiger Kabesch, A ^a   Lang, T ^b   Hartl, D ^a   Hector, A ^a   Glasmacher, C ^c   Griese, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Children's Hospital Starnberg   (Germany)

^c Medicomp Gesellschaft für Versuchsplanung und Datenanalyse   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INCIDENCE; INFANT; LIVER FIBROSIS; LIVER FUNCTION TEST; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CYSTIC FIBROSIS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84863323022     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05177.x     Document Type: Article

References (36)

1. Colombo C, Battezzati PM,. Hepatobiliary manifestations of cystic fibrosis. Eur J Gastroenterol Hepatol 1996; 8: 748-54. (Pubitemid 26275692)
2. Gooding I, Dondos V, Gyi KM, Hodson M, Westaby D,. Variceal hemorrhage and cystic fibrosis: outcomes and implications for liver transplantation. Liver Transpl 2005; 11: 1522-6. (Pubitemid 43072628)
3. Efrati O, Barak A, Modan-Moses D, et al,. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003; 15: 1073-8. (Pubitemid 37267221)
4. Colombo C, Apostolo MG, Assaisso M, Roman B, Bottani P,. Liver disease in cystic fibrosis. Neth J Med 1992; 41: 119-22.
5. Sinaasappel M,. Hepatobiliary pathology in patients with cystic fibrosis. Acta Paediatr Scand Suppl 1989; 363: 45-50.
6. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG,. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105: 1857-64. (Pubitemid 24002805)
7. Kowdley KV,. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000; 108: 481-6. (Pubitemid 30214200)
8. Colombo C, Setchell KD, Podda M, et al,. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990; 117: 482-9. (Pubitemid 20315682)
9. Cotting J, Lentze MJ, Reichen J,. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990; 31: 918-21. (Pubitemid 20269543)
10. Kumar D, Tandon RK,. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol 2001; 16: 3-14. (Pubitemid 32120928)
11. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A,. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15: 677-84.
12. Shimokura GH, McGill JM, Schlenker T, Fitz JG,. Ursodeoxycholate increases cytosolic calcium concentration and activates Cl- currents in a biliary cell line. Gastroenterology 1995; 109: 965-72.
13. Colombo C, Crosignani A, Assaisso M, et al,. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992; 16: 924-30.
14. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A,. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23: 1484-90. (Pubitemid 26181232)
15. Nakagawa M, Colombo C, Setchell KD,. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990; 12: 322-34. (Pubitemid 20285797)
16. Nousia-Arvanitakis S, Fotoulaki M, Economou H, Xefteri M, Galli-Tsinopoulou A,. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001; 32: 324-8. (Pubitemid 32231728)
17. van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP,. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997; 32: 369-73. (Pubitemid 27156175)
18. Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK,. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int 2007; 27: 1402-8. (Pubitemid 350142255)
19. Cheng K, Ashby D, Smyth R,. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 1999; 3: CD000222.
20. Lindblad A, Glaumann H, Strandvik B,. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998; 27: 166-74. (Pubitemid 28041550)
21. Prader A, Largo RH, Molinari L, Issler C,. Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl 1989; 52: 1-125.
22. Schumann G, Klauke R,. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: preliminary upper reference limits obtained in hospitalized subjects. Clin Chim Acta 2003; 327: 69-79. (Pubitemid 35447818)
23. Siekmann L, Bonora R, Burtis CA, et al,. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate dehydrogenase, alanine aminotransferase and creatine kinase accord. Clin Chem Lab Med 2002; 40: 739-45.
24. Schumann G, Bonora R, Ceriotti F, et al,. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 6. Reference procedure for the measurement of catalytic concentration of gamma-glutamyltransferase. Clin Chem Lab Med 2002; 40: 734-8.
25. Colombo C, Battezzati PM, Crosignani A, et al,. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36: 1374-82. (Pubitemid 35403528)
26. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F,. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004; 41: 920-5. (Pubitemid 39575658)
27. Colombo C, Apostolo MG, Ferrari M, et al,. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994; 124: 393-9. (Pubitemid 24094449)
28. Weickert U, Buttmann A, Jakobs R, Schilling D, Eickhoff A, Riemann JF,. Diagnosis of liver cirrhosis: a comparison of modified ultrasound and laparoscopy in 100 consecutive patients. J Clin Gastroenterol 2005; 39: 529-32. (Pubitemid 40863649)
29. Maurage C, Lenaerts C, Weber A, Brochu P, Yousef I, Roy CC,. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989; 9: 17-20. (Pubitemid 19166684)
30. van der PD, Kwok A, Lam T, et al,. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J 2006; 36: 692-9. (Pubitemid 44563429)
31. Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R,. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol 2006; 40: 521-7. (Pubitemid 44318137)
32. Gaskin KJ, Waters DL, Howman-Giles R, et al,. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med 1988; 318: 340-6. (Pubitemid 18044162)
33. Lindblad A, Glaumann H, Strandvik B,. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30: 1151-8. (Pubitemid 29510852)
34. Corbett K, Kelleher S, Rowland M, et al,. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr 2004; 145: 327-32. (Pubitemid 39165680)
35. Newman TB, Browner WS, Cummings SR, Hulley SB,. Designing an observational study: cross-sectional and case-control studies. In:, Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB, eds. Designing Clinical Research. Philadelphia: Lippincott Williams & Wilkins, 2001; 107-20.
36. Fogarty A, Hubbard R, Britton J,. International comparison of median age at death from cystic fibrosis. Chest 2000; 117: 1656-60. (Pubitemid 30413359)